A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
PriLOSEC
(United States) [Available]Synonyms :
omeprazole
Class :
Drugs for peptic ulcer & Proton pump inhibitors
Brand Name :
PriLOSEC
(United States) [Available]Synonyms :
omeprazole
Class :
Drugs for peptic ulcer & Proton pump inhibitors
Gastroesophageal Reflux Disease (GERD)
20
mg
every day
4
weeks
Gastroesophageal Reflux Disease (GERD)
weight (5-10 kg):
5
mg
orally
every day
weight (10-20 kg): 10 mg orally every day
weight (>20 kg): 20 mg orally every day
antacids may reduce the absorption of quinolones
antacids may reduce the absorption of quinolones
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
antacids: they may diminish the bioavailability of corticosteroids
omeprazole: they may enhance serum concentrations of cilostazol
omeprazole: they may enhance the serum concentration of citalopram
may diminish the bioavailability when combined with corticosteroids
may diminish the bioavailability when combined with corticosteroids
may diminish the bioavailability when combined with corticosteroids
may diminish the bioavailability when combined with corticosteroids
may diminish the bioavailability when combined with corticosteroids
when both drugs are combined, there may be a decrease in levels of serum concentration and absorption of erlotinib
it may reduce the therapeutic effect of bisacodyl
it may decrease the serum concentration of belumosudil
it may decrease the serum concentration of bosutinib
may decrease the serum concentration
may diminish the absorption of iron preparations
may diminish the serum concentration
may reduce the rate of bioavailability of corticosteroids
may reduce the rate of bioavailability of corticosteroids
may reduce the rate of bioavailability of corticosteroids
may reduce the rate of bioavailability of corticosteroids
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
cefuroxime: they may diminish the serum concentration of antacids
chloroquine: they may diminish the serum concentration of antacids
antacids: they may diminish the serum concentration of dabigatran
lanthanum carbonate: they may decrease the therapeutic effect of antacids
ledipasvir: they may diminish the serum concentration of antacids
potassium phosphate: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
dasatinib: they may diminish the serum concentration of antacids
belumosudil: they may diminish the serum concentration of antacids
belumosudil: they may diminish the serum concentration of Inhibitors of the Proton Pump
may decrease the diagnostic effect of each other when combined
bismuth subgallate: they may decrease the therapeutic effect of antacids
cabotegravir: they may diminish the absorption of antacids
erdafitinib: they may diminish the serum concentration of antacids
fosinopril: they may diminish the serum concentration of antacids
neratinib: they may diminish the serum concentration of antacids
octreotide: they may diminish the serum concentration of antacids
phosphate binders: they may diminish the serum concentration of antacids
phosphate binders: they may diminish the serum concentration of antacids
phosphate binders: they may diminish the serum concentration of antacids
tetraferric tricitrate decahydrate
phosphate binders: they may diminish the serum concentration of antacids
phosphate binders: they may diminish the serum concentration of antacids
riociguat: they may diminish the serum concentration of antacids
sulpiride: they may diminish the serum concentration of antacids
omeprazole: they may decrease the antiplatelet effect of clopidogrel
may reduce the time of elimination and increase the serum concentration of methotrexate
may reduce the time of elimination and increase the serum concentration of trimetrexate
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of omeprazole
antacids decrease the concentration of cefditoren in serum
they decrease the concentration of rilpivirine in the serum
may decrease the serum concentration
antacids can reduce the amount of cefditoren present in the bloodstream
levonorgestrel: they may diminish the serum concentration of antacids
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
antacids reduce the excretion of amphetamines
antacids reduce the excretion of amphetamines
antacids reduce the excretion of amphetamines
antacids reduce the excretion of amphetamines
antacids reduce the excretion of amphetamines
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
antacids may reduce the serum concentration of multivitamins
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the bioavailability
may decrease the bioavailability
may decrease the bioavailability
may decrease the bioavailability
may decrease the bioavailability
may decrease the bioavailability
may decrease the bioavailability
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
omeprazole: they may enhance the serum concentration of cyclosporine
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
sodium picosulfate, citric acid, and magnesium oxide
antacids: they may decrease the therapeutic effect of laxative
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
when both drugs are combined, there may be an increased risk of hypomagnesemia
fedratinib increases the effect of omeprazole by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
it may decrease the excretion of amphetamines
Proton Pump inhibitors may increase the absorption of amphetamine
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may decrease the serum concentration of Multivitamins
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
may increase the serum concentration of itraconazole
they decrease the efficacy of cysteamine
cefpodoxime: they may diminish the serum concentration of antacids
captopril: they may diminish the serum concentration of antacids
rosuvastatin: they may diminish the serum concentration of antacids
mesalamine: they may diminish the serum concentration of antacids
it enhances the level of bismuth subsalicylate by increasing the gastrointestinal absorption
it enhances the effect of alprazolam by diminishing the metabolism
they decrease the concentration of active metabolites of infigratinib in the serum
Actions and spectrum:
Actions:
Omeprazole belongs to a group of drugs called substituted benzimidazoles. It reduces stomach acid production. Omeprazole stops an enzyme called H+/K+ ATPase from working properly. This enzyme helps make stomach acid. As a proton-pump inhibitor, Omeprazole attaches to specific parts of the H+/K+ ATPase enzyme. This blocks stomach acid production for up to 36 hours. Omeprazole lowers both normal and stimulated acid secretion in the stomach. The reduction in acid secretion depends on the dose taken. Omeprazole works to reduce stomach acid regardless of what caused the increased acid production.
Spectrum:
Omeprazole tackles many stomach and esophagus issues. It treats acid reflux, heartburn, and too much stomach acid. Omeprazole kills bacteria called H. pylori that causes ulcers. It helps heal damage from stomach acid. Omeprazole is used for active ulcers in the stomach or small intestine.
Frequency defined:
1%-10%
Abdominal pain
Constipation
Diarrhea
Nausea
Dizziness
Headache
<1%:
Bradycardia
Chest pain
Pruritis
Decreased libido
Diabetes mellitus
Goiter
Abdominal distension
Black Box Warning
But, taking omeprazole long-term may raise the risk of bone fractures. A warning says long use needs careful watch for this risk. So, doctors must weigh the benefits against potential dangers of using omeprazole over a long time.
Contraindication/Caution:
Contraindication:
Hypersensitivity
Caution:
Diarrhea associated with Clostridium difficile
Systemic lupus erythematosus
Cutaneous lupus erythematosus
Inhibition of hepatic isoenzyme CYP2C19
Pain in joints may develop
Increased risk of infections due to Campylobacter, Salmonella, etc.
Acute tubulointerstitial nephritis
Pregnancy consideration:
Lactation:
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
<b>Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Omeprazole is one of the proton pump inhibitor drugs. It was the very first medicine in this group. As a proton pump inhibitor, it works by specifically blocking the proton pumps found in stomach lining cells called parietal cells. By stopping these pumps, omeprazole lowers the amount of acid released into the stomach. This lessens the overall acid levels. Omeprazole powerfully reduces acid production through this action. That makes it key for treating issues caused by too much stomach acid, like GERD, peptic ulcers, and other conditions with excessive acid secretion.
Pharmacodynamics:
Omeprazole acts by joining to the H+/K+ ATPase found in stomach cells. It stops this enzyme from working. This prevents acid from being made in the stomach. Omeprazole treats acid reflux disease, ulcers, and other acid issues. It blocks the last step of stomach acid production. By doing this, it lowers stomach acid levels. This is how omeprazole works to treat stomach problems caused by too much acid.
Pharmacokinetics:
Absorption
Omeprazole is a drug that treats stomach acid problems. Around 30-40% of the medicine gets absorbed into your body. It starts reducing stomach acid within one hour after taking it. The highest level in your blood occurs 0.5 to 3.5 hours later.
Distribution
95-96% of omeprazole binds to proteins in your body. Its distribution volume is 0.39 liters per kilogram.
Metabolism
The liver breaks down omeprazole extensively using the CYP2C19 enzyme. This produces metabolites like omeprazole sulfone and hydroxyomeprazole. Omeprazole sulfide is an inactive byproduct.
Elimination and excretion
Most omeprazole (77%) leaves your body through urine. Some exits via feces through bile. Omeprazole’s total clearance ranges from 500 to 600 milliliters per minute. Its half-life, the time for half the drug to be eliminated, is usually 0.5 to 1 hour. However, with liver problems, this can increase to 3 hours.
Administration:
Omeprazole must be taken by mouth. It’s best to have it half an hour before meals or as told by your doctor. You should take the prescribed amount at the right time. This will help omeprazole work well. Don’t take omeprazole for more than two weeks unless told so by your physician. Following directions carefully ensures omeprazole’s benefits. It also reduces risks of taking it too long.
Patient information leaflet
Generic Name: Omeprazole
Pronounced: Au-me-pra-zole
Why do we use omeprazole?
Omeprazole prevents stomach acid from being released. It does this by stopping proton pumps from working. These pumps make stomach acid, so omeprazole stops acid from being made. This helps people with esophagitis, acid reflux, ulcers, and bacterial infections like Helicobacter pylori. The acid can damage the esophagus, stomach lining, and duodenum. By blocking acid production, omeprazole allows healing and relief for acid-related problems in the gut.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
